open access
The effect of nitro-oleic versus losartan in diabetic nephropathy: modulation of parathyroid hormone-related protein
Affiliations- Department of Physiology, Faculty of Medicine, Cairo University, Egypt
- Department of Biochemistry, Faculty of Medicine, Cairo University, Egypt
- Department of Anatomy and Embrology, Faculty of Medicine, Cairo University, Egypt
open access
Abstract
Background: Parathyroid hormone-related protein (PTHrP) involvement in the mechanisms related to angiotensin II (AngII)-induced renal injury has become an emerging concern. The current study was thus designed to compare the possible preventive and therapeutic effect of AngII antagonists, losartan and nitro-oleic (NO2-OA) acid, on diabetic nephropathy (DN) and evaluate their effect on PTHrP modulation as well as on the functional and histopathological parameters in the kidney of diabetic rats.
Materials and methods: Forty eight adult male Sprague Dawley rats were divided into control group, DN group, pre-diabetic nephropathy (pre-DN) losartan group, pre-diabetic nephropathy nitro-oleic acid (pre-DN NO2-OA) group, post-diabetic nephropathy (post-DN) losartan and post-diabetic nephropathy nitro-oleic acid (post-DN NO2-OA) groups. At the end of the study, systolic blood pressure (SBP), serum fasting glucose, glomerular filtration rate (GFR), urea, urea albumin excretion (UAE), serum angiotensin, renal PTHrP gene expression and correlations between PTHrP and SBP, serum glucose, AngII and kidney functions were evaluated. Histo- logical examination, Masson’s trichrome, periodic acid-Schiff staining as well as morphometric analysis and histopathological scoring for tubular and glomerular parameters have been carried out.
Results: Prophylactic losartan and NO2-OA were associated with improvement in SBP, serum glucose, urea, GFR, UAE, with reduction in serum AngII and PTHrP overexpression observed in diabetic kidney. Treatment with losartan and NO2-OA showed the same effect except that post-DN NO2-OA showed no significant effect regarding kidney function. Strong correlations were observed between PTHrP and SBP, serum glucose, AngII and kidney functions. Histopathological results revealed obvious improvement in glomerulosclerosis, vascular and tubular injury parameters in prophylactic groups especially with losartan.
Conclusions: Both pre and post-DN losartan, NO2-OA may have a potential role in protection and regression of DN through reduction of PTHrP overexpression.
Abstract
Background: Parathyroid hormone-related protein (PTHrP) involvement in the mechanisms related to angiotensin II (AngII)-induced renal injury has become an emerging concern. The current study was thus designed to compare the possible preventive and therapeutic effect of AngII antagonists, losartan and nitro-oleic (NO2-OA) acid, on diabetic nephropathy (DN) and evaluate their effect on PTHrP modulation as well as on the functional and histopathological parameters in the kidney of diabetic rats.
Materials and methods: Forty eight adult male Sprague Dawley rats were divided into control group, DN group, pre-diabetic nephropathy (pre-DN) losartan group, pre-diabetic nephropathy nitro-oleic acid (pre-DN NO2-OA) group, post-diabetic nephropathy (post-DN) losartan and post-diabetic nephropathy nitro-oleic acid (post-DN NO2-OA) groups. At the end of the study, systolic blood pressure (SBP), serum fasting glucose, glomerular filtration rate (GFR), urea, urea albumin excretion (UAE), serum angiotensin, renal PTHrP gene expression and correlations between PTHrP and SBP, serum glucose, AngII and kidney functions were evaluated. Histo- logical examination, Masson’s trichrome, periodic acid-Schiff staining as well as morphometric analysis and histopathological scoring for tubular and glomerular parameters have been carried out.
Results: Prophylactic losartan and NO2-OA were associated with improvement in SBP, serum glucose, urea, GFR, UAE, with reduction in serum AngII and PTHrP overexpression observed in diabetic kidney. Treatment with losartan and NO2-OA showed the same effect except that post-DN NO2-OA showed no significant effect regarding kidney function. Strong correlations were observed between PTHrP and SBP, serum glucose, AngII and kidney functions. Histopathological results revealed obvious improvement in glomerulosclerosis, vascular and tubular injury parameters in prophylactic groups especially with losartan.
Conclusions: Both pre and post-DN losartan, NO2-OA may have a potential role in protection and regression of DN through reduction of PTHrP overexpression.
Keywords
diabetic nephropathy; losartan; nitro-oleic acid; angiotensin II; parathyroid hormone related protein
About this articleTitle
The effect of nitro-oleic versus losartan in diabetic nephropathy: modulation of parathyroid hormone-related protein
Journal
Issue
Article type
Original article
Pages
79-90
Published online
2018-07-03
Page views
1983
Article views/downloads
959
DOI
Pubmed
Bibliographic record
Folia Morphol 2019;78(1):79-90.
Keywords
diabetic nephropathy
losartan
nitro-oleic acid
angiotensin II
parathyroid hormone related protein
Authors
A. S. Mohammed
N. B. Sadek
M. A. Eshra
E. A. H. Khowailed
L. A. Rashed
B. E. Aboulhoda
References (27)- Ando K, Fujita T. Anti-diabetic effect of blockade of the renin-angiotensin system. Diabetes Obes Metab. 2006; 8(4): 396–403.
- Ardura JA, Rayego-Mateos S, Rámila D, et al. Parathyroid hormone-related protein promotes epithelial-mesenchymal transition. J Am Soc Nephrol. 2010; 21(2): 237–248.
- Bosch RJ, Ortega A, Izquierdo A, et al. A transgenic mouse model for studying the role of the parathyroid hormone-related protein system in renal injury. J Biomed Biotechnol. 2011; 2011: 290874.
- Chen YT, Tsai TH, Yang CC, et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med. 2013; 11(1): 270.
- Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl. 2002; 8(2): 91–109.
- Fiaschi-Taesch NM, Santos S, Reddy V, et al. Prevention of acute ischemic renal failure by targeted delivery of growth factors to the proximal tubule in transgenic mice: the efficacy of parathyroid hormone-related protein and hepatocyte growth factor. J Am Soc Nephrol. 2004; 15(1): 112–125.
- Gojo A, Utsunomiya K, Taniguchi K, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007; 568(1-3): 242–247.
- Izquierdo A, López-Luna P, Ortega A, et al. The parathyroid hormone-related protein system and diabetic nephropathy outcome in streptozotocin-induced diabetes. Kidney Int. 2006; 69(12): 2171–2177.
- Ji Z, Huang C, Liang C, et al. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis. Cell Mol Immunol. 2005; 2(2): 150–154.
- Jin HM, Pan Yu. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant. 2007; 22(7): 1943–1949.
- Kobori H, Mori H, Masaki T, et al. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013; 19(17): 3033–3042.
- Liu Y, Jia Z, Liu S, et al. Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice. Am J Physiol Renal Physiol. 2013; 305(11): F1555–F1562.
- Lorenzo O. Angiotensin II Increases Parathyroid Hormone-Related Protein (PTHrP) and the Type 1 PTH/PTHrP Receptor in the Kidney. J Am Soc Nephrol. 2002; 13(6): 1595–1607.
- Noda, M., Katoh, T., Takuwa, N., Synergistic stimulation of parathyroid hormone-related peptide gene expression by mechanical stretch and angiotensin II in rat aortic smooth muscle cells. J Biol Chem. 1994; 269(27): 17911–17917.
- Park JT, Kang SW. Oxidative stress, the capo of endothelial dysfunction in chronic renovascular hypertension. Kidney Res Clin Pract. 2014; 33(1): 1–2.
- Pirola CJ, Wang HM, Kamyar A, et al. Angiotensin II regulates parathyroid hormone-related protein expression in cultured rat aortic smooth muscle cells through transcriptional and post-transcriptional mechanisms. J Biol Chem. 1993; 268(3): 1987–1994.
- Pyle L. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013; 36(6): 1735–1741.
- Raile K, Galler A, Hofer S, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007; 30(10): 2523–2528.
- Romero M, Ortega A, Olea N, et al. Novel role of parathyroid hormone-related protein in the pathophysiology of the diabetic kidney: evidence from experimental and human diabetic nephropathy. J Diabetes Res. 2013; 2013: 162846.
- Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol. 2005; 288(6): F1183–F1190.
- Tang SCW, Chan GCW, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res. 2016; 5.
- Wadei HM, Mai ML, Ahsan N, et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006; 1(5): 1066–1079.
- Wang W, Li C, Yang T. Protection of nitro-fatty acid against kidney diseases. Am J Physiol Renal Physiol. 2016; 310(8): F697–F704.
- Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013; 62(9): 3224–3231.
- Welsch S, Schordan E, Coquard C, et al. Abnormal renovascular parathyroid hormone-1 receptor in hypertension: Primary defect or secondary to angiotensin ii type 1 receptor activation? Endocrinology. 2006; 147(9): 4384–4391.
- Yazgan ÜC, Taşdemir E, Bilgin HM, et al. Comparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes. Arch Physiol Biochem. 2015; 121(4): 157–161.
- Zhang J, Villacorta L, Chang L, et al. Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res. 2010; 107(4): 540–548.
